X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OVX836 is Osivax’ broad-spectrum influenza A vaccine candidate, in combination with quadrivalent influenza vaccines is being evaluated for the treatment of Influenza.
Lead Product(s): OVX836,Inactivated quadrivalent influenza vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
OVX033 is a first-in-class coronavirus vaccine candidate that targets the nucleocapsid (N), a highly conserved internal antigen. Unlike surface antigens such as Spike (S), N is much less likely to mutate, providing a broader and more universal immune response.
Lead Product(s): OVX033
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX033
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
The funding will support preclinical studies evaluating the breadth of protection and immune response induced by the company’s lead, broad-spectrum influenza vaccine candidate, OVX836 against pandemic influenza strains.
Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 05, 2023
Details:
OVX836, a first-in-class broad-spectrum influenza vaccine candidate that targets the nucleoprotein (NP), a highly conserved internal antigen, is being evaluated in combination with Quadrivalent Influenza Vaccines (QIVs).
Lead Product(s): OVX836,Influenza Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
The funding will support additional research and development of its lead, broad-spectrum influenza vaccine candidate, OVX836 that targets the nucleoprotein (NP), a highly conserved internal antigen.
Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 28, 2023
Details:
OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.
Lead Product(s): OVX836
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
OVX836, targets the nucleoprotein (NP), a highly conserved internal antigen. Unlike surface antigens, NP is much less likely to mutate, providing a broader and more universal immune response.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
Osivax will apply the funds to prepare OVX836 for a Phase 2b field efficacy clinical trial to assess its efficacy against a broad range of circulating strains. OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Funding June 23, 2022
Details:
OVX836 is Osivax’ T-cell based influenza candidate developed using the company’s proprietary oligoDOM® nanoparticle technology platform and designed to produce immune responses against the nucleoprotein (NP), a highly conserved internal antigen across flu strains.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
Details:
Under the collaboration, NIAID will provide its self-assembling ferritin nanoparticles that serve as scaffolding to display multiple copies of HA protein, expressed on the surface of influenza viruses, to Osivax for in vivo preclinical studies in combination with OVX836.
Lead Product(s): OVX836,Quadrivalent Seasonal Influenza Subunit Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: OVX836
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
